Azenta Reports Fourth Quarter and Full Year Results for Fiscal 2026, Ended September 30, 2026.
Key Highlights
- ➤FY27 revenue guidance $648-$660 million, with organic growth expected at 3%-5%
- ➤FY27 adjusted EBITDA margin expansion projected at 200-250 basis points year over year
- ➤FY26 revenue $622 million, up 5% year over year; organic growth reached 2%
- ➤FY26 adjusted EBITDA $58.3 million, down 12%; margin declined to 9.4%
- ➤Elegen agreements could deploy approximately $32.0-$71.0 million for gene synthesis expansion
Expert Statements
Dr. Martin Madaus, Interim President and Chief Executive Officer of Azenta
“We closed fiscal 2026 with improving momentum, delivering stronger performance in the second half of the year. Our businesses have strong market positions and differentiated capabilities, and we are seeing progress from our efforts to improve commercial execution and operating efficiency,”
Dr. Martin Madaus, Interim President and Chief Executive Officer of Azenta
“We also took several actions to streamline our cost structure while advancing the strategic objective to turn Multiomics into a growth engine for Azenta.”
Dr. Martin Madaus, Interim President and Chief Executive Officer of Azenta
“Fiscal 2027 is about consistent execution and accelerating performance. We are focused on driving organic growth, expanding profitability and cash generation, and executing on our strategic initiatives.”
Azenta Reports Fourth Quarter and Full Year Results for Fiscal 2026, Ended September 30, 2026. PR Newswire
* Q4'26 reported revenue growth of 5% year over year and 2% on an organic basis * FY'26 reported revenue growth of 5% year over year and 2% on an organic basis * FY'27 reported revenue expected to range from $648 to $660 million * FY'27 organic revenue growth expected to range between 3% to 5% year over year * FY'27 adjusted EBITDA margin expected to expand approximately 200 to 250 basis points year over year BURLINGTON, Mass., Nov. 10, 2026 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today reported financial results for the fourth quarter and fiscal year ended September 30, 2026. B Medical Systems is reported as discontinued operations, with its historical results reflected in total diluted EPS. The Company completed the sale of the business on July 1, 2026, and received full repayment of the $35 million vendor loan, together with accrued interest, on September 3, 2026.
Get started
Create a free account to read the full story.